BACKGROUND: The goals of the treatment of @entity121 are to shorten the time of healing and to avoid relapses. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) in the healing of @entity121 . MATERIALS AND METHODS: A multicentre, randomised, double-blind, parallel, controlled clinical trial was conducted in 71 @entity1 (81.8% males) aged 45.6 (SD=10.0) years with @entity121 in the legs and haematoma. The haematoma was evacuated in all @entity1 . Thirty-three @entity1 were randomised to a single dose of autologous PRP and 38 @entity1 to simulation of PRP administration. The primary end-point was time to complete recovery of @entity121 . Secondary end-points were @entity158 , relapses, ultrasound parameters, and adverse events. The total follow-up per @entity1 was 12 months. RESULTS: Time to complete recovery after the treatment was 31.63 days (SD=15.38) in the PRP group, and 38.43 days (SD=18.58) in the control group (p=0.261). @entity158 decreased over time in both groups without statistical differences between them. Eight @entity1 relapsed (seven in the control group, and one in the PRP group). There were no adverse effects related to the interventions. DISCUSSION: Autologous PRP did not significantly improve the time to healing compared to that in the control group.

Efficacy of autologous platelet-rich plasma for the treatment of XXXX with haematoma: a multicentre, randomised, double-blind, placebo-controlled clinical trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle tears', 'muscle injury', 'muscle injuries'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain']
@entity121 :: (MESH:D009135,Disease) :: ['muscle rupture']
